Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies.

Q3 Medicine Electrolyte and Blood Pressure Pub Date : 2014-12-01 Epub Date: 2014-12-31 DOI:10.5049/EBP.2014.12.2.55
Gi-Su Oh, Hyung-Jin Kim, AiHua Shen, Su Bin Lee, Dipendra Khadka, Arpana Pandit, Hong-Seob So
{"title":"Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies.","authors":"Gi-Su Oh,&nbsp;Hyung-Jin Kim,&nbsp;AiHua Shen,&nbsp;Su Bin Lee,&nbsp;Dipendra Khadka,&nbsp;Arpana Pandit,&nbsp;Hong-Seob So","doi":"10.5049/EBP.2014.12.2.55","DOIUrl":null,"url":null,"abstract":"<p><p>Cisplatin is one of the most widely used and highly effective drug for the treatment of various solid tumors; however, it has dose-dependent side effects on the kidney, cochlear, and nerves. Nephrotoxicity is the most well-known and clinically important toxicity. Numerous studies have demonstrated that several mechanisms, including oxidative stress, DNA damage, and inflammatory responses, are closely associated with cisplatin-induced nephrotoxicity. Even though the establishment of cisplatin-induced nephrotoxicity can be alleviated by diuretics and pre-hydration of patients, the prevalence of cisplatin nephrotoxicity is still high, occurring in approximately one-third of patients who have undergone cisplatin therapy. Therefore it is imperative to develop treatments that will ameliorate cisplatin-nephrotoxicity. In this review, we discuss the mechanisms of cisplatin-induced renal toxicity and the new strategies for protecting the kidneys from the toxic effects without lowering the tumoricidal activity. </p>","PeriodicalId":35352,"journal":{"name":"Electrolyte and Blood Pressure","volume":"12 2","pages":"55-65"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5049/EBP.2014.12.2.55","citationCount":"155","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electrolyte and Blood Pressure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5049/EBP.2014.12.2.55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/12/31 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 155

Abstract

Cisplatin is one of the most widely used and highly effective drug for the treatment of various solid tumors; however, it has dose-dependent side effects on the kidney, cochlear, and nerves. Nephrotoxicity is the most well-known and clinically important toxicity. Numerous studies have demonstrated that several mechanisms, including oxidative stress, DNA damage, and inflammatory responses, are closely associated with cisplatin-induced nephrotoxicity. Even though the establishment of cisplatin-induced nephrotoxicity can be alleviated by diuretics and pre-hydration of patients, the prevalence of cisplatin nephrotoxicity is still high, occurring in approximately one-third of patients who have undergone cisplatin therapy. Therefore it is imperative to develop treatments that will ameliorate cisplatin-nephrotoxicity. In this review, we discuss the mechanisms of cisplatin-induced renal toxicity and the new strategies for protecting the kidneys from the toxic effects without lowering the tumoricidal activity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
顺铂所致肾功能障碍及改善治疗策略的展望。
顺铂是治疗各种实体肿瘤最广泛、最有效的药物之一;然而,它对肾脏、耳蜗和神经有剂量依赖性的副作用。肾毒性是临床上最常见和最重要的毒性。大量研究表明,氧化应激、DNA损伤和炎症反应等多种机制与顺铂诱导的肾毒性密切相关。尽管通过利尿剂和患者的预水化可以减轻顺铂引起的肾毒性,但顺铂肾毒性的发生率仍然很高,大约三分之一接受顺铂治疗的患者发生了顺铂肾毒性。因此,开发改善顺铂肾毒性的治疗方法势在必行。在这篇综述中,我们讨论了顺铂诱导肾毒性的机制,以及在不降低杀瘤活性的情况下保护肾脏免受毒性作用的新策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Electrolyte and Blood Pressure
Electrolyte and Blood Pressure Medicine-Internal Medicine
CiteScore
2.10
自引率
0.00%
发文量
0
期刊最新文献
A Case of Recurrent Renal Infarction Following Transient Resolution: Evidence From Serial Computed Tomography. Is Renal Denervation Effective in Treating Resistant Hypertension? Use of Fludrocortisone for Hyperkalemia in Chronic Kidney Disease Not Yet on Dialysis. Fatal Hypermagnesemia in Patients Taking Magnesium Hydroxide. Osmotic Demyelination Syndrome in a High-Risk Patient Despite Cautious Correction of Hyponatremia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1